about
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancerMethodological aspects of the molecular and histological study of prostate cancer: focus on PTENNVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.Stratification and therapeutic potential of PML in metastatic breast cancerGain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug SensitivityA Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer CompoundsResistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.Extracellular superoxide dismutase is a major antioxidant in human fibroblasts and slows telomere shortening.AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activityCyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.Targeting a cell state common to triple-negative breast cancersPI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.Functional transcriptomics: an experimental basis for understanding the systems biology for cancer cells.RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1Cancer network activity associated with therapeutic response and synergism.MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.Development of PI3K inhibitors: lessons learned from early clinical trials.Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?Interrogating open issues in cancer precision medicine with patient-derived xenografts.Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.Analysis of gene expression profiles in melanoma cells with acquired resistance against antineoplastic drugs.The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1.Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.Accelerated telomere shortening in Fanconi anemia fibroblasts--a longitudinal study.High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.Modulation of telomere protection by the PI3K/AKT pathway.Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.
P50
Q24338724-80F1E02A-A80B-4AF6-B4FA-55B4D7ECF7AAQ27005677-BC782408-B207-4F8F-A778-5C24E281748FQ27851451-BB4117A8-C035-4DC6-B2D2-BE30CB92B8E8Q28387589-AEC0A493-EC06-4786-92B6-39189F91B632Q28553888-68F9A406-B2E5-41B4-919D-06BB44ADDF09Q28598343-6F7E3F4C-C9F2-4C1F-9C63-A03E2AF93DCBQ33659361-30B6949C-FB2B-462E-8B75-59D5E5296A88Q33660573-2D0793BD-6BF5-4AEA-B271-AEABAAA09D0DQ34163867-AE43FE95-159A-4F10-B6CB-DCB1D9CA0F1DQ34511038-BE9BF143-CC6D-41DF-9DAA-359AA816151AQ34621219-BC6E2FD2-74F8-435A-9620-C2E76C1D9F73Q34736064-535F4AFB-DE54-4250-87EC-83DCC674B62FQ35174128-2DBC72A7-89E5-4396-A21A-000FC92DAB52Q35610581-AB883A2E-A057-46AC-A7AB-9783B3F37093Q36750362-F6F7019A-39B6-452E-B7C2-463E732BC88CQ36891050-5E2B2BAC-6903-4475-AB9A-BA035CD0AC80Q36921422-F96821E3-0992-4C86-86B7-8702736012A6Q36983065-BB4B9779-F6AB-4C07-BFF1-446F3AB90EF4Q37137914-FCC67430-5AB1-42CA-B879-8CB615C15541Q37199267-C43114BC-F28D-40C6-875C-2CCC2B13816CQ37381179-9191678C-FC91-45A1-B80C-CB4C2495530CQ37445131-7D433FAB-C7F1-49D1-8B7B-D8C3705A5994Q37605004-4A508EFA-DB40-4ECC-93DB-8758D025BA8EQ38080710-F44876B5-EE26-4448-BB23-128AE734B5B0Q38205751-1E0F76D7-07EF-4F2B-8DE6-9B33369558DFQ38735131-83B7F5E5-B711-4E3C-A8B8-E24D5A18C289Q38741697-0123BACD-A22A-4C72-8416-2580549957A2Q39095733-8FF2020E-302B-4E84-8E1E-50F3EEC7EC82Q39381586-60D07229-C3BB-4C1B-8D00-8C40CAAC06CFQ39579978-E31A6E6F-8790-4650-AD96-BB54D38ED4A3Q40299252-0A1D653B-76FF-4D83-B233-C82A7544D973Q40351356-7841F723-1D47-402C-9817-7EC955DDF7BDQ40393334-EE1A343A-CBB1-4A7B-B37E-36E937BCBED7Q40776262-58806BBD-2858-48A3-84AA-9997D0A60D1DQ41735415-D4DF8EDA-2212-4300-9968-3076D05CC964Q43898530-3CB380A6-B553-47F4-B97A-1D7499422D1AQ45257167-C8AC2D8E-39AD-4D0F-84E5-9B4C05CD4ED2Q45329468-58C2AC74-97AC-4BD7-8881-ABDC3BD6DF73Q45341269-12796035-C3A8-488C-BECD-164DF7976245Q45903260-26DDA145-8E57-4653-A240-BD9A1EC3A4D6
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Violeta Serra
@ast
Violeta Serra
@en
Violeta Serra
@es
Violeta Serra
@nl
Violeta Serra
@sl
type
label
Violeta Serra
@ast
Violeta Serra
@en
Violeta Serra
@es
Violeta Serra
@nl
Violeta Serra
@sl
prefLabel
Violeta Serra
@ast
Violeta Serra
@en
Violeta Serra
@es
Violeta Serra
@nl
Violeta Serra
@sl
P106
P1153
7004067678
P21
P31
P496
0000-0001-6620-1065